Ecovyst Raised the Bar Again - but the Free Cash Flow Story Is Still New

Ecovyst reported second-quarter results today and raised its full-year 2026 outlook across the board - revenue, adjusted EBITDA, and adjusted EPS. Q2 revenue came in at $250 million, above the $237 million consensus. Adjusted EPS of $0.21 cleared the 19-cent estimate. The company lifted its full-year adjusted EBITDA guidance from $180 million–$195 million to $195 million–$207 million, revenue from $890 million–$970 million to $1.02 billion–$1.06 billion, and adjusted EPS from $0.50–$0.65 to $0.58–$0.72.

The stock is up 42 percent over the past year. For a business that lost money on a GAAP basis through most of 2024 and 2025, that move already reflects an improving narrative. The question now is whether the free cash flow path - the thing that actually separates a turnaround from a tape trade - is far enough along to justify sitting inside it.

The old story

If you last looked at Ecovyst during the heavy loss quarters of 2024 and 2025, the picture was ugly. GAAP losses were mounting. The market was absorbing the tail end of a messy transition period - the company divested its Advanced Materials & Catalysts business (including its stake in Zeolyst) in December 2025, and that segment had been a persistent drag. The advanced materials unit generated its own set of earnings volatility, and stripping it out left a smaller, simpler company with a high-debt balance sheet.

Debt to equity sits at 68 percent. Total debt is $671 million against $575 million in equity. GAAP earnings are still deeply negative on a trailing basis, which is why the forward P/E reads as 277 times - a number that looks absurd until you understand it reflects impairment charges and one-time costs from the restructuring, not the ongoing economics of the sulfuric acid core.

The market has been treating this as a turnaround story. Turnaround stories are easy to trade off headlines and hard to price correctly because the cash-flow bridge takes time to materialize.

The new reality

The numbers from the last two quarters tell a different story than the ones that were generating losses.

Sales have jumped from $215 million in Q1 2026 to $250 million in Q2 2026. That's a $35 million quarter-over-quarter increase, and the first-half revenue of $465 million annualizes to $930 million, which is below the new full-year guidance range of $1.02 billion–$1.06 billion. Regeneration services - Ecovyst's business of processing waste sulfuric acid from refineries and selling it back - is benefiting from high refinery utilization rates, favorable alkylate economics, and lower customer downtime. Virgin sulfuric acid volumes rose more than 30 percent in Q1 and have continued climbing, helped by new production capacity at Waggaman, Louisiana, that came online this year.

Adjusted EBITDA - earnings before interest, taxes, depreciation, and amortization, plus back out certain one-time charges - in Q2 2026 pushed higher. On a trailing twelve-month basis, EBITDA margin is 19.4 percent. That's not spectacular for a specialty chemical business, but solid for one that was posting losses just two years ago.

The one metric that matters most for the thesis is free cash flow. Trailing twelve-month FCF sits at $70 million, down 26 percent year-over-year. That headline decline looks like a negative, but it's a function of heavy near-term capex - the Waggaman investment, two additional projects totaling about $20 million announced in Q1, and the Calabrian acquisition that closed in June. Q1 2026 adjusted free cash flow swung from minus $13 million a year earlier to plus $4 million, a $17 million reversal in a single quarter. Once capex normalizes after these projects come online, FCF has room to grow materially from here.

The raised guidance makes this explicit. The midpoint of the new adjusted EBITDA range is $201 million - up from the old midpoint of $187.5 million. The midpoint of the new adjusted EPS range is $0.65 - up from $0.575. These aren't cosmetic adjustments. They reflect the revenue ramp and margin structure that were already showing up in Q1 and Q2.

Why the market hasn't fully moved

Despite the two consecutive beats, the raised outlook, and the FCF swing from negative to positive, Ecovyst trades at $12.11 - roughly where it was in late July, before today's release. Year-to-date, the stock is up 24 percent, which is solid but not euphoric.

There are reasons for the cautious posture. The Calabrian acquisition adds unknown integration risk, and the deal terms haven't been disclosed. The debt load is still elevated relative to equity. GAAP losses mean the earnings multiples look broken. And specialty chemical businesses that depend on refinery utilization and mining demand carry cyclical risk - a downturn in those end markets would compress volumes and pricing simultaneously.

AInvest's aggregate rating sits at Buy, with a composite analysis score of 3.96 out of 5 and a fundamental rating of just 2.97. That gap between the analyst consensus and the fundamental score suggests the aggregate view is anchored on the improving trajectory even though the underlying fundamentals haven't fully graduated from turnaround territory. That mismatch is exactly where this setup lives.

The financial bridge

If we work off the raised guidance, the math is straightforward. The midpoint of the new FY26 adjusted EBITDA range is $201 million. Ecovyst's enterprise value is $1.56 billion. That puts the stock at approximately 7.8 times forward adjusted EBITDA.

That is a discount to many specialty chemical peers, most of which trade at 10x–14x EBITDA. For context, Ecovyst's own trailing EV/EBITDA is 11.7 times - so the market is assigning a lower multiple going forward than it does to the current run rate, despite guidance that's higher than the trailing numbers. That doesn't make sense unless investors are still writing off the improvement as fragile.

If adjusted EBITDA hits the $201 million midpoint and the multiple reverts to the current trailing level of roughly 11.7x, that implies enterprise value of roughly $2.35 billion. Subtract net debt of $230 million and you get equity value of about $2.12 billion. On roughly 109 million shares outstanding (derived from the $1.325 billion market cap and $12.11 share price), that works out to roughly $19.50 per share.

That number is not a target I'm slapping on the stock today. The gap between $12 and $20 is material but narrow enough to be honest. Simple forward multiples are cleaner than DCF models - which are just the illusion of control anyway. But they still require an assumption about what happens after the current capex period ends.

A more conservative bridge uses the bottom of the EBITDA range ($195 million) at a more modest 10x multiple. That gives EV of $1.95 billion, equity value of $1.72 billion, and a price near $15.75. Even that is roughly 30 percent above the current share price. The real test isn't whether the math works - it's whether the operating setup can sustain the improvement.

What would prove this right

Three things need to hold over the next 12 months:

Refinery utilization stays high. Regeneration services are Ecovyst's largest revenue contributor. High refinery utilization means more waste acid to process, more alkylate production, and more contract renewals at favorable pricing. If refinery margins compress and downtime increases, volumes drop and pricing pressure follows.

Capex normalizes. The Waggaman expansion, the two Q1 projects, and the Calabrian integration are all front-loaded spending. Once these come online and the company transitions back to maintenance-level capex, FCF should expand sharply. If additional investments are announced that extend the heavy spending period, the cash-flow improvement gets delayed.

Virgin acid volumes hold. The 30-plus percent volume growth in virgin sulfuric acid is driven by solid demand and the Waggaman contribution. If mining or industrial demand weakens, that growth rate slows.

What could break it

A cyclical downturn in refinery margins or mining activity. A heavier-than-expected Calabrian integration bill. Or persistent capex that keeps FCF from expanding as quickly as the EBITDA numbers suggest.

The setup is clear: the business is generating positive cash flow from operations after posting negative numbers in the same quarter a year ago. Revenue is trending toward the top end of the raised guidance range in just two quarters. And the market is applying a lower forward multiple than the current trailing one despite the improvement.

That is the kind of gap between operating evidence and market pricing that inflection trades are built on. Whether it sustains depends on whether the refinery cycle cooperates and the capex cycle ends on schedule. The financial path is explicit enough to follow. The risk is specific enough to monitor.

Tripwire: if Q3 revenue falls below $220 million or adjusted EBITDA drops below $30 million, the volume-and-pricing story has cracked and the inflection case is over.